-CHOH), 4.95 (t, J 5.4 Hz, 1H, -CH2OH), 4.53 (dd, J 2.1,
(d, J 7.0 Hz, 2H), 5.23 (d, J 5.1 Hz, 1H, -CHOH), 4.87 (t, J
5.2 Hz, 1H, -CH2OH), 4.19 (dd, J 2.4, 13.5 Hz, 1H, lower field
branch of AB quartet, -NCH2), 3.92 (dd, J 8.0, 13.5 Hz, 1H,
higher field branch of AB quartet, -NCH2), 3.72 (m, 1H,
-CHOH), 3.36–3.44 (m, 1H, lower field branch of AB quartet,
-CH2OH), 3.22–3.27 (m, 1H, higher field branch of AB quartet,
-CH2OH). 13C NMR (d6-DMSO) d 155.7 (CQ), 141.4 (CH),
118.9 (CQ), 112.6 (CH), 70.8 (CH), 63.1 (CH2), 60.2 (CH2), 43.5
(CQ).
12.9 Hz, 1H, lower field branch of AB quartet, -NCH2), 4.23
(dd, J 8.8, 12.9 Hz, 1H, higher field branch of AB quartet,
-NCH2), 3.89 (m, 1H, -CHOH), 3.46–3.53 (m, 1H, lower field
branch of AB quartet, -CH2OH), 3.31–3.39 (m, 1H, higher field
branch of AB quartet, -CH2OH). 13C NMR (d6-DMSO) d
184.1 (CQ), 163.9 (CQ), 149.7 (CH), 140.6 (CQ), 130.8 (CH),
119.1 (CH), 110.9 (CQ), 98.1 (CQ) 70.8 (CH), 63.4 (CH2), 61.7
(CH2).
4-[1-(2,3-Dihydroxypropyl)-3,5-diiodopyridin-4(1H)-ylidene]-3-
phenylisoxazol-5(4H)-one, 18a. Purified by recrystallisation
from ethanol to give an orange-yellow microcrystalline
powder (0.28 g, 25%), mp 223.5–225 uC (Found: MHz m/z
564.90888; C17H14I2N2O4 requires MHz m/z 564.91159;
D ~ 4.8 ppm). lmax 432 (H2O); 456 (methanol) log10e 3.51;
466 (10% aqueous acetonitrile); 492 (DMSO) log10e 3.71; 490
[1-(2,3-Dihydroxypropyl)-3,5-diiodopyridin-4(1H)-ylidene]di-
cyanomethane, 21. Purified by recrystallisation from ethanol to
give yellow platelets (0.39 g, 49%), mp 263–264 uC (Found:
MHz m/z 469.88491; C11H9I2N3O2 requires MHz m/z
469.88571; D ~ 1.7 ppm). lmax 404 (H2O–acetone; 20 : 1); 410
(methanol) log10e 4.16; 410 (acetonitrile); 412 (DMSO) log10e
4.22; 412 (acetone); 416 (pyridine). 1H NMR (d6-DMSO) d 8.53
(s, 2H), 5.24 (d, J 5.6 Hz, 1H, -CHOH), 4.85 (t, J 5.4 Hz, 1H,
-CH2OH), 4.23 (dd, J 2.6, 13.3 Hz, 1H, lower field branch of
AB quartet, -NCH2), 3.96 (dd, J 8.4, 12.3 Hz, 1H, higher field
branch of AB quartet, -NCH2), 3.73–3.75 (m, 1H, -CHOH),
3.38–3.46 (m, 1H, lower field branch of AB quartet, -CH2OH),
3.24–3.31 (m, 1H, higher field branch of AB quartet, -CH2OH).
13C NMR (d6-DMSO) d 154.8 (CQ), 149.5 (CH), 119.6 (CQ),
83.2 (CQ), 70.6 (CH), 63.2 (CH2), 59.9 (CH2). One quaternary
carbon signal, -C(CN)2, not observed.
1
(5% aqueous acetone); 510 (pyridine). H NMR (d6-DMSO) d
9.05 (s, 1H), 9.01 (s, 1H), 7.27–7.36 (m, 3H), 7.16–7.19 (m, 2H),
5.43 (d, J 5.7 Hz, 1H, -CHOH), 4.94 (t, J 5.4 Hz, 1H,
-CH2OH), 4.52 (dd, J 2.6, 13.0 Hz, 1H, lower field branch of
AB quartet, -NCH2), 4.23 (dd, J 8.7, 13.0 Hz, 1H, higher field
branch of AB quartet, -NCH2), 3.86–3.88 (m, 1H, -CHOH),
3.45–3.52 (m, 1H, lower field branch of AB quartet, -CH2OH),
3.33 (m, 1H, higher field branch of AB quartet, -CH2OH). 13
C
NMR (d6-DMSO) d 171.1 (CQ), 161.8 (CQ), 160.6 (CQ), 150.2
(CH), 149.8 (CH), 134.3 (CQ), 128.9 (CH), 128.8 (CH), 126.3
(CH), 99.1 (CQ), 98.8 (CQ), 91.9 (CQ), 70.6 (CH), 63.4 (CH2),
61.9 (CH2).
5-[1-(2,3-Dihydroxypropyl)-3,5-diiodopyridin-4(1H)-ylidene]-
1,3-diethyl-2-thiobarbituric acid, 22. Isolated by concentrating
the crude product mixture to dryness and then stirring the
residual solids in hot acetone–hexanes (1 : 1). The resulting
precipitate was collected by filtration and washed with hot
hexanes to give an orange-yellow powder (119 mg, 10%).
Recrystallisation (isopropanol) afforded bright orange micro-
crystals, mp 265–266 uC (Found: MHz m/z 603.92656;
C16H19I2N3O4S requires MHz m/z 603.92586; D ~ 0.7 ppm).
lmax 414 (H2O); 438 (methanol) log10e 3.93; 458 (acetonitrile);
448 (DMSO) log10e 3.94; 462 (acetone); 468 (pyridine). 1H
NMR (d6-DMSO) d 9.19 (s, 2H), 5.48 (d, J 5.7 Hz, 1H,
-CHOH), 4.97 (t, J 5.4 Hz, 1H, -CH2OH), 4.61–4.64 (m, 1H,
lower field branch of AB quartet, -NCH2), 4.44 (q, J 6.4 Hz,
4H, -NCH2CH3), 4.32 (dd, J 9.0, 12.8 Hz, 1H, higher field
branch of AB quartet, -NCH2), 3.91 (m, 1H, -CHOH), 3.47–
3.54 (m, 1H, lower field branch of AB quartet, -CH2OH), 3.35–
3.39 (m, 1H, higher field branch of AB quartet, -CH2OH), 1.19
(t, J 6.7 Hz, 6H, -NCH2CH3). 13C NMR (d6-DMSO) d 176.3
(CQ), 166.4 (CQ), 156.8 (CQ), 150.2 (CH), 130.2 (CQ), 103.0
(CQ), 70.7 (CH), 63.5 (CH2), 62.6 (CH2), 41.6 (CH2), 13.1
(CH3).
4-[1-(2,3-Dihydroxypropyl)-3,5-diiodopyridin-4(1H)-ylidene]-
3-tert-butylisoxazol-5(4H)-one, 18b. Purified by recrystallisa-
tion from methanol to give orange platelets (0.21 g, 19%), mp
278–280 uC (Found: C, 32.29; H, 3.35; N, 4.87. C15H18-
I2N2O4?½H2O requires C, 32.57; H, 3.46; N, 5.06%) (Found:
MHz m/z 544.94108; C15H18I2N2O4 requires MHz m/z
544.94289; D ~ 3.3 ppm). lmax 448 (H2O); 486 (methanol)
log10e 2.81; 488 (10% aqueous acetonitrile); 554 (DMSO) log10e
3.09; 556 (5% aqueous acetone); 550 (pyridine). 1H NMR
(d6-DMSO) d 9.28 (s, 1H), 9.23 (s, 1H), 5.51 (d, J 5.7 Hz, 1H,
-CHOH), 4.98 (t, J 5.4 Hz, 1H, -CH2OH), 4.59 (dd, J 2.4,
12.8 Hz, 1H, lower field branch of AB quartet, -NCH2), 4.31–
4.35 (m, 1H, higher field branch of AB quartet, -NCH2), 3.92
(m, 1H, -CHOH), 3.40–3.43 (m, 1H, lower field branch of AB
quartet, -CH2OH), 3.32–3.37 (m, 1H, higher field branch of AB
quartet, -CH2OH), 1.09 (9H, -CH3). 13C NMR (d6-DMSO) d
195.0 (CQ), 167.3 (CQ), 166.2 (CQ), 150.0 (CH), 149.7 (CH),
105.9 (CQ), 105.7 (CQ), 93.0 (CQ), 70.6 (CH), 63.4 (CH2), 62.6
(CH2), 33.4, (CQ), 30.2, (CH3).
4-[1-(2,3-Dihydroxypropyl)-3,5-diiodopyridin-4(1H)-ylidene]-
3-tert-butyl-1-phenylpyrazol-5(4H)-one, 19. Obtained as a red
powder, which on filtration and exposure to air gradually
changed to a crimson, glassy-like solid (0.624 g, 50%) (Found:
MHz m/z 619.99386; C21H23I2N3O3 requires MHz m/z
619.99017; D ~ 6.0 ppm). lmax 536 (3 : 1; H2O–DMSO); 536
(methanol) log10e 2.99; 542 (49 : 1; acetonitrile–DMSO); 548
(DMSO) log10e 3.05; 542 (49 : 1; acetone–DMSO); 558 (49 : 1;
1-(2-Hydroxyethyl)-4-(phenylthio)pyridinium iodide, 13
A mixture of 4-(phenylthio)pyridine (5.61 g, 0.03 mol) and
2-iodoethanol (5.16 g, 0.03 mol) in solution in isopropanol
(15 mL) was refluxed for 3 days, after which time it was cooled
and concentrated to give a yellow oil. This was triturated with
ether (15 mL) and then cooled until a solid mass had formed.
The solid was recovered by filtration and washed thoroughly
with ether to afford 1-(2-hydroxyethyl)-4-(phenylthio)pyridi-
nium iodide as a beige solid (10.57 g, 98%) which was
acceptable for use without further purification. Recrystallisa-
tion from a methanol–isopropanol mixture gave the salt as off-
white microcrystals, mp 166–167.5 uC (Found: C, 43.48; H,
3.82; N, 3.87. C13H14INOS requires C, 43.46; H, 3.93; N,
1
pyridine–DMSO). Due to poor resolution H and 13C NMR
spectra were not helpful and therefore are not reported here.
2-[1-(2,3-Dihydroxypropyl)-3,5-diiodopyridin-4(1H)-ylidene]-
indane-1,3-dione, 20. Purified by recrystallisation from ethanol
to give an orange powder (0.09 g, 8%), mp 235–237 uC (Found:
C, 37.10; H, 2.88; N, 2.36. C17H13I2NO4 requires C, 37.19; H,
2.39; N, 2.55%) (Found: MHz m/z 549.89899; C17H13I2NO4
requires MHz m/z 549.90069; D ~ 3.1 ppm). lmax 432 (H2O);
444 (methanol) log10e 3.96; 468 (acetonitrile); 464 (DMSO)
log10e 4.14; 470 (acetone); 476 (pyridine). 1H NMR (d6-DMSO)
d 9.02 (s, 2H), 7.33–7.43 (m, 4H), 5.44 (d, J 5.7 Hz, 1H,
1
3.90%); H NMR (CDCl3) d 8.85 (d, J 7.1 Hz, 2H), 7.58–7.63
(m, 5H), 7.38 (d, J 7.1 Hz, 2H), 4.88 (t, J 4.8 Hz, 2H), 4.13 (br s,
1H), 4.05 (m, 2H). 13C NMR (CDCl3), d 165.1 (CQ), 143.6
(CH), 135.9 (CH), 132.2 (CH), 131.5 (CH), 125.7 (CQ), 122.8
(CH), 62.3 (CH2), 61.1 (CH2).
J. Mater. Chem., 2001, 11, 2271–2281
2279